Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent i...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Kai Fu, Fachao Xie, Fang Wang and Liwu Fu Tags: Review Source Type: research